Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AVI-6003 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| AVI-6003 | EXPERIMENTAL | Phosphorodiamidate morpholino antisense oligomer with positive charges on selected subunits (PMOplus™) |
| Placebo | PLACEBO_COMPARATOR | Normal saline |
| Name | Type | Description |
|---|---|---|
| AVI-6003 | DRUG | Single intravenous administration |
| Placebo | DRUG | Single intravenous administration |
Inclusion Criteria: * Male or female and between the ages of 18 and 50 years in good general health * Volunteers must be willing to use barrier methods of contraception or be of non-childbearing potential * Volunteers must be willing to undergo a urine screen for drugs of abuse Exclusion Criteria:...
AVI-6003 is an investigational small molecule being developed for Marburg Hemorrhagic Fever, a severe infectious disease. It is intended as a post-exposure prophylaxis treatment for Marburg virus infection. The drug is currently in Phase 1 clinical development and has not been approved by regulatory authorities.
AVI-6003 is being developed by Sarepta Therapeutics, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol SRPT. The company is conducting clinical research on this investigational drug for the treatment of Marburg Hemorrhagic Fever.
AVI-6003 is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA or any other regulatory agency. The drug is being studied for safety and tolerability in healthy volunteers as a potential post-exposure prophylaxis for Marburg virus infection.
AVI-6003 has one completed Phase 1 clinical trial, identified as NCT01353040, titled 'Safety Study of Single Administration Post-exposure Prophylaxis Treatment for Marburg Virus.' This randomized, double-blind, placebo-controlled study enrolled 30 healthy adult volunteers in the United States and evaluated the safety of the drug.
AVI-6003 is a small molecule therapeutic being developed as a post-exposure prophylaxis for Marburg virus infection. The specific molecular target of AVI-6003 has not been disclosed in available clinical trial information, so its precise mechanism of action is not publicly detailed.